Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.
Gori N, Ippoliti E, Ferrucci SM, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Di Nardo L, Antonelli F, Coscarella G, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Chiricozzi A, Peris K; MEDaCoTRA Study Group. Gori N, et al. Among authors: seremet t. J Eur Acad Dermatol Venereol. 2024 Feb 29. doi: 10.1111/jdv.19929. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38421043 No abstract available.
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study.
Chiricozzi A, Ferrucci SM, Di Nardo L, Gori N, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Caldarola G, De Simone C, Ippoliti E, Torres T, Gkalpakiotis S, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Peris K; MEDaCoTRA Study Group. Chiricozzi A, et al. Among authors: seremet t. Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1307-1315. doi: 10.1080/14712598.2023.2292627. Epub 2023 Dec 28. Expert Opin Biol Ther. 2023. PMID: 38108300
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.
Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B. Schwarze JK, et al. Among authors: seremet t. Cancers (Basel). 2022 Jan 28;14(3):682. doi: 10.3390/cancers14030682. Cancers (Basel). 2022. PMID: 35158952 Free PMC article.
58 results